Novo expands type 1 diabetes R&D

03:47 EDT 17 May 2018 | pharmaphorum

Novo Nordisk has edged closer to finding a cure for type 1 diabetes and will expand its stem cell research into other chronic disease areas. The Copenhagen-based company’s commitment to expand its focus to serious chronic diseases, as well as type...

Original Article: Novo expands type 1 diabetes R&D


More From BioPortfolio on "Novo expands type 1 diabetes R&D"

Quick Search


Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...